{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:02:51Z","timestamp":1724482971244},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite complex treatment of surgery, radiotherapy and chemotherapy, high grade gliomas often recur. Differentiation between post-treatment changes and recurrence is difficult. <jats:sup>18<\/jats:sup>F-methyl-choline (<jats:sup>18<\/jats:sup>F-FCH) is frequently used in staging and detection of recurrent prostate cancer disease as well as some brain tumours; however accumulation in inflammatory tissue limits its specificity. The <jats:sup>18<\/jats:sup>F-ethyl-tyrosine (<jats:sup>18<\/jats:sup>F-FET) shows a specific uptake in malignant cells, resulting from increased expression of amino acid transporters or diffusing through the disrupted blood-brain barrier. <jats:sup>18<\/jats:sup>F-FET exhibits lower uptake in machrophages and other inflammatory cells. Aim of this study was to evaluate <jats:sup>18<\/jats:sup>F-FCH and <jats:sup>18<\/jats:sup>F-FET uptake by human glioblastoma T98G cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Material and methods<\/jats:title>\n                  <jats:p>Human glioblastoma T98G or human dermal fibroblasts cells, seeded at a density to obtain 2 \u00d7 10<jats:sup>5<\/jats:sup> cells per flask when radioactive tracers were administered, grew adherent to the plastic surface at 37\u00b0C in 5% CO<jats:sub>2<\/jats:sub> in complete medium. Equimolar amounts of radiopharmaceuticals were added to cells for different incubation times (20 to 120 minutes) for <jats:sup>18<\/jats:sup>F-FCH and <jats:sup>18<\/jats:sup>F-FET respectively. The cellular radiotracer uptake was determined with a gamma counter. All experiments were carried out in duplicate and repeated three times. The uptake measurements are expressed as the percentage of the administered dose of tracer per 2 \u00d7 10<jats:sup>5<\/jats:sup> cells. Data (expressed as mean values of % uptake of radiopharmaceuticals) were compared using parametric or non-parametric tests as appropriate. Differences were regarded as statistically significant when p&lt;0.05.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A significant uptake of <jats:sup>18<\/jats:sup>F-FCH was seen in T98G cells at 60, 90 and 120 minutes. The percentage uptake of <jats:sup>18<\/jats:sup>F-FET in comparison to <jats:sup>18<\/jats:sup>F-FCH was lower by a factor of more than 3, with different kinetic curves.<jats:sup>18<\/jats:sup>F-FET showed a more rapid initial uptake up to 40 minutes and <jats:sup>18<\/jats:sup>F-FCH showed a progressive rise reaching a maximum after 90 minutes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                     <jats:sup>18<\/jats:sup>F-FCH and <jats:sup>18<\/jats:sup>F-FET are candidates for neuro-oncological PET imaging. <jats:sup>18<\/jats:sup>F-FET could be the most useful oncological PET marker in the presence of reparative changes after therapy, where the higher affinity of <jats:sup>18<\/jats:sup>F-FCH to inflammatory cells makes it more difficult to discriminate between tumour persistence and non-neoplastic changes. Additional studies on the influence of inflammatory tissue and radionecrotic cellular components on radiopharmaceutical uptake are necessary.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/raon-2016-0022","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T08:12:24Z","timestamp":1524211944000},"page":"153-158","source":"Crossref","is-referenced-by-count":3,"title":["<sup>18<\/sup>F-FET and <sup>18<\/sup>F-FCH uptake in human glioblastoma T98G cell lines"],"prefix":"10.1515","volume":"50","author":[{"given":"Marco Giovanni","family":"Persico","sequence":"first","affiliation":[{"name":"Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica Eleonora","family":"Buroni","sequence":"additional","affiliation":[{"name":"Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pasi","sequence":"additional","affiliation":[{"name":"Department of Oncohaematology, Radiotherapy Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Lodola","sequence":"additional","affiliation":[{"name":"Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Aprile","sequence":"additional","affiliation":[{"name":"Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Nano","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotecnology \u201cLazzaro Spallanzani\u201d, University of Pavia, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Hodolic","sequence":"additional","affiliation":[{"name":"Nuclear medicine research department, Iason, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"2021040721433245413_j_raon-2016-0022_ref_001_w2aab3b8c51b1b7b1ab2ab1Aa","unstructured":"Purves D, Augustine GJ, Fitzpatrick D, Katz LC, LaMantia AS, McNamara JO, et al. Neuroscience (2nd edition) Sunderland (MA): Sinauer Associates; 2001."},{"key":"2021040721433245413_j_raon-2016-0022_ref_002_w2aab3b8c51b1b7b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010; 28: 3838-43.","DOI":"10.1200\/JCO.2010.30.0582"},{"key":"2021040721433245413_j_raon-2016-0022_ref_003_w2aab3b8c51b1b7b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"Chaichana KL, McGirt MJ, Laterra J, Olivi A, Qui\u00f1ones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010; 112: 10-7.","DOI":"10.3171\/2008.10.JNS08608"},{"key":"2021040721433245413_j_raon-2016-0022_ref_004_w2aab3b8c51b1b7b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"Wick W, Stupp R, Beule AC, Bromberg J, Wick A, Ernemann U, et al. A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 2008; 10: 1019-24.","DOI":"10.1215\/15228517-2008-058"},{"key":"2021040721433245413_j_raon-2016-0022_ref_005_w2aab3b8c51b1b7b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009; 253:486-96.","DOI":"10.1148\/radiol.2532090007"},{"key":"2021040721433245413_j_raon-2016-0022_ref_006_w2aab3b8c51b1b7b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol 2012; 198: 19-26.","DOI":"10.2214\/AJR.11.7417"},{"key":"2021040721433245413_j_raon-2016-0022_ref_007_w2aab3b8c51b1b7b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885-9.","DOI":"10.1148\/radiology.144.4.6981123"},{"key":"2021040721433245413_j_raon-2016-0022_ref_008_w2aab3b8c51b1b7b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, et al. Cerebral necrosis after radiotherapy and\/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988; 150: 189-97.","DOI":"10.2214\/ajr.150.1.189"},{"key":"2021040721433245413_j_raon-2016-0022_ref_009_w2aab3b8c51b1b7b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002; 12: 615-26.","DOI":"10.1016\/S1052-5149(02)00033-3"},{"key":"2021040721433245413_j_raon-2016-0022_ref_010_w2aab3b8c51b1b7b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: Is it useful? J Neurol Neurosurg Psychiatry 1995; 58: 250-2.","DOI":"10.1136\/jnnp.58.2.250"},{"key":"2021040721433245413_j_raon-2016-0022_ref_011_w2aab3b8c51b1b7b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F. Overexpression of choline kinase is a frequent feature in human tumor derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2000; 296: 580-3.","DOI":"10.1016\/S0006-291X(02)00920-8"},{"key":"2021040721433245413_j_raon-2016-0022_ref_012_w2aab3b8c51b1b7b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K. Brain tumors: detection with C-11 choline PET. Radiology 1997; 202: 497\u2013503.","DOI":"10.1148\/radiology.202.2.9015080"},{"key":"2021040721433245413_j_raon-2016-0022_ref_013_w2aab3b8c51b1b7b1ab2ac13Aa","unstructured":"Sollini M, Sghedoni R, Erba PA, Cavuto S, Froio A, De Berti G, et al. Diagnostic performances of [18F]fluorocholine positron emission tomography in brain tumors. Q J Nucl Med Mol Imaging 2015; Sep 1 [Epub ahead of print]; PMID: 26329494."},{"key":"2021040721433245413_j_raon-2016-0022_ref_014_w2aab3b8c51b1b7b1ab2ac14Aa","unstructured":"Friedland RP, Mathis CA, Budinger TF. Labelled choline and phosphorycholine: Body distribution and brain autoradiography. J Nucl Med 1983; 24:812-5."},{"key":"2021040721433245413_j_raon-2016-0022_ref_015_w2aab3b8c51b1b7b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Wyss MT, Weber B, Honer M, Sp\u00e4th N, Ametamey SM, Westera G, et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 3: 312-6.","DOI":"10.1007\/s00259-003-1337-4"},{"key":"2021040721433245413_j_raon-2016-0022_ref_016_w2aab3b8c51b1b7b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Oxender DL, Christensen HN. Distinct mediating systems for the transport of neutral amino acids by the Ehrlich cell. J Biol Chem 1963; 238: 3686-99.","DOI":"10.1016\/S0021-9258(19)75327-7"},{"key":"2021040721433245413_j_raon-2016-0022_ref_017_w2aab3b8c51b1b7b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Kaim AH, Weber B, Kurrer MO, Westera G, Schweitzer A, Gottschalk J, et al. 18F-FDG and 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med 2002; 29: 648-54.","DOI":"10.1007\/s00259-002-0780-y"},{"key":"2021040721433245413_j_raon-2016-0022_ref_018_w2aab3b8c51b1b7b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Buck D, F\u00f6rschler A, Lapa C, Schuster T, Vollmar P, Korn T, et al. 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. J Nucl Med 2012; 53: 1269-76.","DOI":"10.2967\/jnumed.111.102608"},{"key":"2021040721433245413_j_raon-2016-0022_ref_019_w2aab3b8c51b1b7b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Messing-J\u00fcnger AM, Floeth FW, Pauleit D, Reifenberger G, Willing R, G\u00e4rtner J, et al. Multimodal target point assessment for stereo-tactic biopsy in children with diffuse bithalamic astrocytomas. Child\u2019s Nerv Syst 2002; 18:445-9.","DOI":"10.1007\/s00381-002-0644-6"},{"key":"2021040721433245413_j_raon-2016-0022_ref_020_w2aab3b8c51b1b7b1ab2ac20Aa","unstructured":"Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, M\u00fcller HW, et al. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alphamethyl-L-tyrosine SPECT in brain tumors. J Nucl Med 2004; 45: 374-81."},{"key":"2021040721433245413_j_raon-2016-0022_ref_021_w2aab3b8c51b1b7b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"P\u00f6pperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannsp\u00f6tter M, et al. O-(2-(18F)fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005; 32: 1018-25.","DOI":"10.1007\/s00259-005-1819-7"},{"key":"2021040721433245413_j_raon-2016-0022_ref_022_w2aab3b8c51b1b7b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"P\u00f6pperl G, G\u00f6tz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al. Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006; 33: 792-800.","DOI":"10.1007\/s00259-005-0053-7"},{"key":"2021040721433245413_j_raon-2016-0022_ref_023_w2aab3b8c51b1b7b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011; 30: 176-84.","DOI":"10.1016\/j.ijrobp.2010.01.055"},{"key":"2021040721433245413_j_raon-2016-0022_ref_024_w2aab3b8c51b1b7b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, B\u00e4rtschi E, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 2009; 95: 87-93.","DOI":"10.1007\/s11060-009-9896-2"},{"key":"2021040721433245413_j_raon-2016-0022_ref_025_w2aab3b8c51b1b7b1ab2ac25Aa","doi-asserted-by":"crossref","unstructured":"Yao KC, Komata T, Kondo Y, Kanzawa T, Kondo S, Germano IM. Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg 2003; 98: 378-84.","DOI":"10.3171\/jns.2003.98.2.0378"},{"key":"2021040721433245413_j_raon-2016-0022_ref_026_w2aab3b8c51b1b7b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"Stein GH. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J Cell Physiol 1979; 99: 43-54.","DOI":"10.1002\/jcp.1040990107"},{"key":"2021040721433245413_j_raon-2016-0022_ref_027_w2aab3b8c51b1b7b1ab2ac27Aa","unstructured":"Buroni FE, Pasi F, Persico MG, Lodola L, Aprile C, Nano R. Evidence of 18F-FCH uptake in human T98G glioblastoma cell line. Anticancer Res 2015; 35: 64438."},{"key":"2021040721433245413_j_raon-2016-0022_ref_028_w2aab3b8c51b1b7b1ab2ac28Aa","doi-asserted-by":"crossref","unstructured":"Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, Treyer V, et al. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007; 48:608-14.","DOI":"10.2967\/jnumed.106.036251"},{"key":"2021040721433245413_j_raon-2016-0022_ref_029_w2aab3b8c51b1b7b1ab2ac29Aa","doi-asserted-by":"crossref","unstructured":"Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K, et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L:-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging 2006; 33: 673-82.","DOI":"10.1007\/s00259-005-0045-7"},{"key":"2021040721433245413_j_raon-2016-0022_ref_030_w2aab3b8c51b1b7b1ab2ac30Aa","doi-asserted-by":"crossref","unstructured":"Bolcaen J, Descamps B, Deblaere K, Boterberg T, De Vos Pharm F, Kalala JP, et al. (18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study. Nucl Med Biol 2015; 42:38-45.","DOI":"10.1016\/j.nucmedbio.2014.07.006"},{"key":"2021040721433245413_j_raon-2016-0022_ref_031_w2aab3b8c51b1b7b1ab2ac31Aa","doi-asserted-by":"crossref","unstructured":"Wang L, Lieberman BP, Ploessl K, Kung HF. Synthesis and evaluation of 18F labelled FET prodrugs for tumor imaging. Nucl Med Biol 2014; 41: 58-67.","DOI":"10.1016\/j.nucmedbio.2013.09.011"},{"key":"2021040721433245413_j_raon-2016-0022_ref_032_w2aab3b8c51b1b7b1ab2ac32Aa","doi-asserted-by":"crossref","unstructured":"Wang HE, Wu SY, Chang CW, Liu RS, Hwang LC, Lee TW, et al. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model. Nucl Med Biol 2005; 32: 367-75.","DOI":"10.1016\/j.nucmedbio.2005.01.005"},{"key":"2021040721433245413_j_raon-2016-0022_ref_033_w2aab3b8c51b1b7b1ab2ac33Aa","doi-asserted-by":"crossref","unstructured":"Habermeier A, Graf J, Sandh\u00f6fer BF, Boissel JP, Roesch F, Closs EI. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids 2015; 47: 335-44.","DOI":"10.1007\/s00726-014-1863-3"},{"key":"2021040721433245413_j_raon-2016-0022_ref_034_w2aab3b8c51b1b7b1ab2ac34Aa","unstructured":"Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F] fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999; 40: 1367-73."},{"key":"2021040721433245413_j_raon-2016-0022_ref_035_w2aab3b8c51b1b7b1ab2ac35Aa","doi-asserted-by":"crossref","unstructured":"Bansal A, Shuyan W, Hara T, Harris RA, Degrado TR. Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats. Eur J Nucl Med Mol Imaging 2008; 35: 1192-203.","DOI":"10.1007\/s00259-008-0736-y"},{"key":"2021040721433245413_j_raon-2016-0022_ref_036_w2aab3b8c51b1b7b1ab2ac36Aa","doi-asserted-by":"crossref","unstructured":"St\u00f6ber B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006; 33: 932-9.","DOI":"10.1007\/s00259-005-0047-5"},{"key":"2021040721433245413_j_raon-2016-0022_ref_037_w2aab3b8c51b1b7b1ab2ac37Aa","doi-asserted-by":"crossref","unstructured":"van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008; 14: 3326-39.","DOI":"10.2174\/138161208786549399"},{"key":"2021040721433245413_j_raon-2016-0022_ref_038_w2aab3b8c51b1b7b1ab2ac38Aa","doi-asserted-by":"crossref","unstructured":"Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006; 33: 287-94.","DOI":"10.1016\/j.nucmedbio.2006.01.002"},{"key":"2021040721433245413_j_raon-2016-0022_ref_039_w2aab3b8c51b1b7b1ab2ac39Aa","unstructured":"Spaeth N, Wyss MT, Weber B, Scheidegger S, Lutz A, Verwey J, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004; 45: 1931-8."},{"key":"2021040721433245413_j_raon-2016-0022_ref_040_w2aab3b8c51b1b7b1ab2ac40Aa","doi-asserted-by":"crossref","unstructured":"Piroth MD, Prasath J, Willuweit A, Stoffels G, Sellhaus B, van Osterhout A, et al. Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. Nucl Med Biol 2013; 40: 795-800.","DOI":"10.1016\/j.nucmedbio.2013.05.001"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/raon.2016.50.issue-2\/raon-2016-0022\/raon-2016-0022.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/raon-2016-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T03:54:51Z","timestamp":1617854091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/raon-2016-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,4,19]]},"published-print":{"date-parts":[[2016,6,1]]}},"alternative-id":["10.1515\/raon-2016-0022"],"URL":"https:\/\/doi.org\/10.1515\/raon-2016-0022","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}